Escherichia coli infection
Therapeutic area
Infectious Disease
Rare disease
No
- Definition
- Infection with the organism Escherichia Coli.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Escherichia coli infection
- Therapeutic area
- Infectious Disease
- escherichia coli infection
- e coli infection
- escherichia coli infection
- Bacterial infection caused by E. coli
- Bacterial infection due to E. coli
- Colibacillosis
- E COLI INFECT
- E coli Infection
- E coli Infections
- E coli infections
- E coli infections, recurrent
- E. coli Infection
- E. coli Infections
- E. coli infection
- ESCHERICHIA COLI INFECT
- Escherichia coli Infections
- INFECT E COLI
- INFECT ESCHERICHIA COLI
- Infection caused by Escherichia coli
- Infection due to Escherichia coli
- Infection, E coli
- Infection, E. coli
- Infection, Escherichia coli
- Infections, E coli
- Infections, Escherichia coli
And 1 more, listed on the interactive page.
- Disease mechanisms
- Acquired
- All therapeutic areas
- Infectious Disease
- Severity
- Severe
- MONDO ID
- MONDO:0020920
- Parent condition
- MONDO:0005113
Related records
Broader conditions (6)
- Bacterial infectious disease
- Disease
- Disease by etiologic mechanism
- Disease of primarily extrinsic mechanism
- Human disease
- Infectious disease
Narrower conditions (1)
- Escherichia coli discitis
Trials (98)
- A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
- A Study Investigating the Safety, Recovery, and Pharmacodynamics of Multiple Oral Administrations of SNIPR001 in Healthy Subjects
- A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
- A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
- Ampicillin-sulbactam Resistant E.Coli at UPMC
- An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
- Antibiotic Resistant Community-Acquired E. Coli
- Assessment of the Prevalence of Extended-Spectrum Betalactamase Producing Enterobacteriaceae Among ICU Staff
- Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
- Bacterial Interference for Prevention of Catheter-Associated UTI: Geriatric Pilot Study
- Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
- Cefotetan Therapy for Escherichia Coli Infections
- Cefuroxime Resistance in Pyelonephritis
- Challenge Study of an ETEC Vaccine
- Characteristics of Lower Respiratory Tract Escherichia Coli Isolates in Mechanically Ventilated Intensive Care Patients
- Characterization of Resistance Against Live-attenuated Diarrhoeagenic E. Coli
- Clinical and Microbiologic Characteristics of Cephalosporin-Resistant E. Coli-PITT Protocol
- Clinical Outcomes in Patients With Infection by Resistant Microorganism
- Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
- Colonizing Neurogenic Bladders With Benign Flora
Drugs in development (4)
- Influenza virus vaccine Phase 3
- Levofloxacin Phase 1
- Sitafloxacin Phase 2
- Urtoxazumab Phase 2
Other linked drugs (2)
- Vibrio cholerae toxin B subunit
- Vibrio cholerae, inactivated